Spectrum Pharmaceuticals (SPPI) Receives Daily Coverage Optimism Score of 0.15
Headlines about Spectrum Pharmaceuticals (NASDAQ:SPPI) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Spectrum Pharmaceuticals earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 46.4636904377721 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news stories that may have effected Accern’s analysis:
- BRIEF-Spectrum Pharmaceuticals provides update on at-the-market facility (reuters.com)
- Spectrum Pharma (SPPI) Says it Issued Approximately 9.3M Shares of Common Stock Under Previously Announced At-The-Market Facility (streetinsider.com)
- SPECTRUM PHARMACEUTICALS INC : Other Events (form 8-K) (4-traders.com)
- Spectrum Pharmaceuticals Provides Update On At-The-Market Facility (thestreet.com)
- Spectrum Pharmaceuticals, Inc. (SPPI)- Safe Haven Investment Performance Stocks – NASDAQ Times (nasdaqtimes.com)
Spectrum Pharmaceuticals (NASDAQ:SPPI) opened at 14.68 on Friday. Spectrum Pharmaceuticals has a one year low of $3.21 and a one year high of $15.32. The stock’s 50 day moving average price is $10.62 and its 200-day moving average price is $7.90. The stock’s market cap is $1.15 billion.
Spectrum Pharmaceuticals (NASDAQ:SPPI) last posted its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.26) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.01. The company had revenue of $34.30 million for the quarter, compared to the consensus estimate of $30.50 million. Spectrum Pharmaceuticals had a negative return on equity of 30.95% and a negative net margin of 59.33%. The firm’s quarterly revenue was up 1.0% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.35) EPS. On average, analysts predict that Spectrum Pharmaceuticals will post ($1.06) earnings per share for the current year.
A number of equities analysts recently issued reports on the company. Zacks Investment Research cut Spectrum Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, August 18th. BidaskClub cut Spectrum Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Jefferies Group LLC set a $9.00 target price on Spectrum Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, August 25th. HC Wainwright lifted their target price on Spectrum Pharmaceuticals from $14.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, ValuEngine upgraded Spectrum Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 17th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. Spectrum Pharmaceuticals presently has an average rating of “Buy” and an average price target of $13.50.
ILLEGAL ACTIVITY WARNING: “Spectrum Pharmaceuticals (SPPI) Receives Daily Coverage Optimism Score of 0.15” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/10/06/spectrum-pharmaceuticals-sppi-receives-daily-coverage-optimism-score-of-0-15.html.
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).
Receive News & Stock Ratings for Spectrum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.